MedTrace Logo

The SHIELD Study-silicosis

NCT05546944 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-09-21

No results posted yet for this study

Summary

An observational cohort study to derive biomarkers which are able to more accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery.

Conditions

  • Silicosis

Sponsors & Collaborators

  • The Prince Charles Hospital

    collaborator OTHER_GOV

  • Royal Prince Alfred Hospital, Sydney, Australia

    collaborator OTHER

  • The Alfred

    collaborator OTHER

  • Austin Hospital, Melbourne Australia

    collaborator OTHER

  • The University of Queensland

    lead OTHER

Principal Investigators

  • Daniel Chambers · The Prince Charles Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-16
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546944 on ClinicalTrials.gov